During the corresponding time, Mesoblast Limited recorded a revenue increase by 191.39 % year on year, While revenue at the Mesoblast Limited's corporate clients
Mesoblast Limited's Comment on Sales, Marketing and Customers
Mesoblast is a commercial-stage biotechnology company with a recently FDA-approved product in the United States. The company emphasizes its values, environmental, social, and governance (ESG) initiatives, and corporate governance. Mesoblast has a business relationship with Lonza.
Mesoblast s Strategic Advancement: U.S. Tariff Exemption and Medical Designations Propel Innovative Cell Therapies New York, April 03, 2025 In a dual win for Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global frontrunner in the advancement of allogeneic cellular medicines for inflammatory diseases, significant strides have been made concerning the company s flagship products amid dynamic regulatory landscapes. While the company elucidates the non-application of U.S. tariffs on its innovative cell therapies, it simultaneously embarks on a strategic path by pursuing critical designations for a pioneering treatment addressing congenital heart disorders.Mesoblast recently announced that the United States Gov...
In a groundbreaking development for the field of regenerative medicine, Mesoblast Limited has announced the FDA approval of RYONCIL (remestemcel-L), marking a significant milestone as the first-ever mesenchymal stromal cell (MSC) therapy in the United States. This approval heralds a new era in the treatment of inflammatory diseases and underscores the potential of cellular therapies to provide innovative solutions for serious medical conditions. The Significance of RYONCIL Approval On December 18, 2024, Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a global leader in allogeneic cellular medicines focused on inflammatory disorders, revealed the landmark approval of RYONCIL. As the only MSC therapy sanctioned by...
The United States Food and Drug Administration (FDA) has recently notified Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, that the available clinical data from its Phase 3 trial supports the submission of a proposed Biologics License Application (BLA) for remestemcel-L. This revolutionary cellular therapy aims to treat steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients.Mesoblast Limited received additional consideration from the FDA, acknowledging the potential of remestemcel-L to effectively address SR-aGVHD, a critical condition affecting children post stem cell transplantation. This decision follows rigorous evaluation of the...
Mesoblast Limited’s Comment on Sales, Marketing and Customers
Mesoblast is a commercial-stage biotechnology company with a recently FDA-approved product in the United States. The company emphasizes its values, environmental, social, and governance (ESG) initiatives, and corporate governance. Mesoblast has a business relationship with Lonza.
Sources:
Mesoblast Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Mesoblast Limited’s corporate clients.
For your research, we’ve provided 9 tables on Mesoblast Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
